Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Consensus Recommendation of "Hold" by Brokerages

Key Points

• Pharming Group has a consensus “Hold” rating from five brokerages: two analysts recommend selling and three recommend buying. The average 1-year price target is $38.67.
• Analyst sentiment is mixed, with Canaccord Genuity raising its target to $38 and maintaining a “Buy,” while Zacks Research downgraded the stock to “Strong Sell”; Oppenheimer maintained an “Outperform” rating.
• Pharming reported quarterly EPS of $0.02, missing the $0.06 consensus estimate. The stock opened at $11.23, near the lower end of its 52-week range, while institutional investors own only 0.03% of shares.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) has earned a consensus recommendation of "Hold" from the five brokerages that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell recommendation and three have assigned a buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $38.6667.

Several research firms have recently weighed in on PHAR. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Pharming Group in a report on Friday, August 7th. Canaccord Genuity Group lifted their price target on shares of Pharming Group from $37.00 to $38.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Zacks Research lowered shares of Pharming Group from a "hold" rating to a "strong sell" rating in a research report on Friday, July 31st. Finally, Oppenheimer reaffirmed an "outperform" rating on shares of Pharming Group in a research note on Thursday, July 30th.

Hedge Funds Weigh In On Pharming Group

A number of institutional investors and hedge funds have recently bought and sold shares of the business. NewEdge Advisors LLC grew its holdings in Pharming Group by 11,310.3% during the 4th quarter. NewEdge Advisors LLC now owns 28,868 shares of the company's stock worth $510,000 after acquiring an additional 28,615 shares during the last quarter. Millennium Management LLC bought a new position in shares of Pharming Group in the fourth quarter worth about $360,000. SmartHarvest Portfolios LLC acquired a new position in shares of Pharming Group during the fourth quarter worth approximately $224,000. Finally, EverSource Wealth Advisors LLC acquired a new position in shares of Pharming Group during the second quarter worth approximately $32,000. Institutional investors and hedge funds own 0.03% of the company's stock.

Pharming Group Price Performance

Pharming Group stock opened at $11.23 on Monday. The business has a 50 day simple moving average of $12.32 and a 200 day simple moving average of $14.03. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31. The company has a market capitalization of $794.86 million, a PE ratio of 93.58 and a beta of 0.01. Pharming Group has a one year low of $9.62 and a one year high of $21.34.

Pharming Group (NASDAQ:PHAR - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.06 by ($0.04). Pharming Group had a net margin of 2.51% and a return on equity of 3.40%. On average, sell-side analysts forecast that Pharming Group will post 0.25 EPS for the current fiscal year.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.